JP2021078504A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021078504A5 JP2021078504A5 JP2021005834A JP2021005834A JP2021078504A5 JP 2021078504 A5 JP2021078504 A5 JP 2021078504A5 JP 2021005834 A JP2021005834 A JP 2021005834A JP 2021005834 A JP2021005834 A JP 2021005834A JP 2021078504 A5 JP2021078504 A5 JP 2021078504A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- identity
- composition according
- clostridium
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022168855A JP7503273B2 (ja) | 2011-12-01 | 2022-10-21 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2024087782A JP2024129016A (ja) | 2011-12-01 | 2024-05-30 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161565976P | 2011-12-01 | 2011-12-01 | |
| US61/565,976 | 2011-12-01 | ||
| US201261607360P | 2012-03-06 | 2012-03-06 | |
| US61/607,360 | 2012-03-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019038453A Division JP7097838B2 (ja) | 2011-12-01 | 2019-03-04 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022168855A Division JP7503273B2 (ja) | 2011-12-01 | 2022-10-21 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021078504A JP2021078504A (ja) | 2021-05-27 |
| JP2021078504A5 true JP2021078504A5 (enExample) | 2022-01-06 |
| JP7165218B2 JP7165218B2 (ja) | 2022-11-02 |
Family
ID=48535050
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014526308A Active JP6306507B2 (ja) | 2011-12-01 | 2012-11-29 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2017213526A Active JP6492151B2 (ja) | 2011-12-01 | 2017-11-06 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2019038453A Active JP7097838B2 (ja) | 2011-12-01 | 2019-03-04 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2021005834A Active JP7165218B2 (ja) | 2011-12-01 | 2021-01-18 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2022168855A Active JP7503273B2 (ja) | 2011-12-01 | 2022-10-21 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2024087782A Pending JP2024129016A (ja) | 2011-12-01 | 2024-05-30 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014526308A Active JP6306507B2 (ja) | 2011-12-01 | 2012-11-29 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2017213526A Active JP6492151B2 (ja) | 2011-12-01 | 2017-11-06 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2019038453A Active JP7097838B2 (ja) | 2011-12-01 | 2019-03-04 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022168855A Active JP7503273B2 (ja) | 2011-12-01 | 2022-10-21 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2024087782A Pending JP2024129016A (ja) | 2011-12-01 | 2024-05-30 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
Country Status (10)
| Country | Link |
|---|---|
| US (12) | US10238694B2 (enExample) |
| EP (4) | EP4477750A3 (enExample) |
| JP (6) | JP6306507B2 (enExample) |
| CN (3) | CN104160014A (enExample) |
| CA (1) | CA2892588A1 (enExample) |
| DK (2) | DK3569690T3 (enExample) |
| ES (2) | ES2994320T3 (enExample) |
| FI (2) | FI3569690T3 (enExample) |
| HK (1) | HK1204008A1 (enExample) |
| WO (1) | WO2013080561A1 (enExample) |
Families Citing this family (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| CA2807242C (en) | 2010-08-04 | 2017-05-02 | Thomas Julius Borody | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| WO2012048152A2 (en) | 2010-10-07 | 2012-04-12 | Mazmanian Sarkis K | Probiotic therapies for autism |
| BR112013022927A2 (pt) | 2011-03-09 | 2016-12-06 | Univ Minnesota | composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| CA2892588A1 (en) | 2011-12-01 | 2013-06-06 | School Corporation, Azabu Veterinary Medicine Educational Institution | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
| IN2014DN07752A (enExample) | 2012-02-29 | 2015-05-15 | Ethicon Endo Surgery Inc | |
| EP2830599B1 (en) | 2012-03-29 | 2018-08-15 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
| US9719144B2 (en) | 2012-05-25 | 2017-08-01 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
| CN114949001A (zh) | 2012-08-29 | 2022-08-30 | 加州理工学院 | 孤独症谱系障碍的诊断和治疗 |
| MX2015006491A (es) | 2012-11-23 | 2015-12-03 | Seres Health Inc | Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas. |
| EP2951283A4 (en) | 2013-02-04 | 2017-01-25 | Seres Therapeutics, Inc. | Compositions and methods |
| MX369877B (es) | 2013-02-04 | 2019-11-25 | Seres Therapeutics Inc | Composiciones y metodos. |
| US9907755B2 (en) | 2013-03-14 | 2018-03-06 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| JP2016519664A (ja) | 2013-03-15 | 2016-07-07 | セレス セラピューティクス インコーポレイテッド | ネットワークを基にした微生物組成物及び方法 |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| MX367109B (es) | 2013-11-25 | 2019-08-05 | Seres Therapeutics Inc | Composiciones bacterianas sinergicas y sus metodos de produccion y usos. |
| US9956282B2 (en) | 2013-12-16 | 2018-05-01 | Seres Therapeutics, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
| WO2015156419A1 (en) | 2014-04-10 | 2015-10-15 | Riken | Compositions and methods for induction of th17 cells |
| US20150322176A1 (en) * | 2014-04-16 | 2015-11-12 | University Of Guelph | Novel polysaccharide immunogens from clostridium bolteae isolated from autistic subjects and methods and uses thereof |
| EP3146065B1 (en) * | 2014-05-19 | 2024-11-13 | Memorial Sloan Kettering Cancer Center | Methods and compositions for reducing clostridium difficile infection |
| US10124025B2 (en) | 2014-10-30 | 2018-11-13 | California Institute Of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
| KR20170086492A (ko) | 2014-10-30 | 2017-07-26 | 캘리포니아 인스티튜트 오브 테크놀로지 | 신경발달 장애에서의 행동을 개선시키기 위한 박테리아를 포함하는 조성물 및 방법 |
| EP4529950A3 (en) | 2014-10-31 | 2025-08-20 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment |
| ES3010296T3 (en) | 2014-11-25 | 2025-04-02 | Memorial Sloan Kettering Cancer Center | Intestinal microbiota and gvhd |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| PE20171138A1 (es) | 2014-12-23 | 2017-08-09 | 4D Pharma Res Ltd | Modulacion inmunitaria |
| DK3193901T3 (en) | 2014-12-23 | 2018-05-28 | 4D Pharma Res Ltd | PIRIN POLYPEPTIDE AND IMMUNMODULATION |
| WO2016110768A1 (en) * | 2015-01-07 | 2016-07-14 | Ecole Polytechnique Federale De Lausanne (Epfl) | Gastro-intestinal biomarkers for diagnosis and therapies of proteinopathies |
| CN114159476A (zh) | 2015-05-14 | 2022-03-11 | 克雷斯顿沃控股公司 | 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置 |
| CN114366759A (zh) | 2015-05-22 | 2022-04-19 | 亚利桑那大学董事会 | 用于治疗自闭症谱系障碍及相关症状的方法 |
| PE20180243A1 (es) * | 2015-06-15 | 2018-01-31 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas |
| EP3662917A1 (en) | 2015-06-15 | 2020-06-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| LT3360559T (lt) | 2015-06-15 | 2019-12-27 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterijų kamienus |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| EA201890097A1 (ru) * | 2015-06-22 | 2018-07-31 | Президент Энд Феллоуз Оф Гарвард Колледж | Индукция регуляторных т-клеток lamina propria |
| WO2018126026A1 (en) | 2016-12-28 | 2018-07-05 | Ascus Biosciences, Inc. | Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon |
| US10851399B2 (en) | 2015-06-25 | 2020-12-01 | Native Microbials, Inc. | Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
| ES2978111T3 (es) | 2015-06-25 | 2024-09-05 | Native Microbials Inc | Métodos, aparatos y sistemas para analizar cepas de microorganismos de comunidades heterogéneas complejas, predecir e identificar relaciones funcionales e interacciones de las mismas, y seleccionar y sintetizar conjuntos microbianos basados en las mismas |
| US9938558B2 (en) | 2015-06-25 | 2018-04-10 | Ascus Biosciences, Inc. | Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
| AU2016321348A1 (en) * | 2015-09-09 | 2018-04-26 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with thyroid health issues |
| KR20180093903A (ko) * | 2015-11-03 | 2018-08-22 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 음식 알레르기의 치료 및/또는 예방을 위한 치료용 미생물총 |
| MA41013A (fr) | 2015-11-20 | 2017-08-30 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) * | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| US20190247447A1 (en) * | 2015-11-24 | 2019-08-15 | Seres Therapeutics, Inc. | Designed bacterial compositions |
| PL3400285T3 (pl) | 2016-01-07 | 2026-05-25 | Native Microbials, Inc. | Sposoby poprawy wytwarzania mleka poprzez podawanie konsorcjów mikrobiologicznych |
| JP6675752B2 (ja) * | 2016-02-23 | 2020-04-01 | 国立大学法人佐賀大学 | 腸内Ｂｌａｕｔｉａ ｃｏｃｃｏｉｄｅｓ増殖刺激剤 |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| MX373290B (es) | 2016-03-04 | 2020-06-18 | 4D Pharma Plc | Composiciones que comprenden cepas bacterianas. |
| AU2017234120B2 (en) | 2016-03-14 | 2024-06-20 | Holobiome, Inc. | Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system |
| US11260083B2 (en) | 2016-03-15 | 2022-03-01 | The Regents Of The University Of Michigan | Compositions and methods for treating and preventing graft versus host disease |
| EP3468391B1 (en) | 2016-06-10 | 2020-12-09 | N.V. Nutricia | Risk of allergy and nutrition to reduce that risk |
| KR102658297B1 (ko) | 2016-06-14 | 2024-04-18 | 베단타 바이오사이언시즈, 인크. | 클로스트리디움 디피실레 감염의 치료 |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US10722600B2 (en) | 2016-06-17 | 2020-07-28 | New York University | Methods and compositions for treating cancer |
| US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| US20180185421A1 (en) * | 2016-08-29 | 2018-07-05 | Tokyo Metropolitan Government | Composition comprising fecal microbiota |
| EP3518946A4 (en) | 2016-09-27 | 2020-09-09 | Board of Regents, The University of Texas System | METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME |
| WO2018071536A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating primary sclerosing cholangitis and related disorders |
| WO2018071537A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US11447738B2 (en) * | 2016-10-28 | 2022-09-20 | Vedanta Biosciences, Inc. | Methods and compositions for preserving bacteria |
| CA3041277A1 (en) * | 2016-11-01 | 2018-05-11 | Keio University | Bacterium capable of inducing th1 cells |
| WO2018094190A2 (en) * | 2016-11-18 | 2018-05-24 | Sanford Burnham Prebys Medical Discovery Institute | Gut microbiota and treatment of cancer |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| WO2018107365A1 (zh) * | 2016-12-13 | 2018-06-21 | 深圳华大基因研究院 | 粪厌氧棒杆菌(Anaerostipes caccae)及其应用 |
| BR112019013125B1 (pt) * | 2016-12-23 | 2022-02-08 | Keio University | Composições farmacêuticas compreendendo uma mistura bacteriana purificada |
| MX2019007760A (es) | 2016-12-28 | 2020-02-10 | Ascus Biosciences Inc | Metodos, aparatos y sistemas para analisis de cepa de microorganismo de comunidades heterogeneas complejas con analisis rastreador, determinacion de relaciones funcionales e interacciones de estas, y sintesis de agrupaciones microbianas que incluyen agrupaciones microbianas dosificadas y agrupaciones microbianas inoculativas. |
| KR20190127710A (ko) * | 2017-02-07 | 2019-11-13 | 캘리포니아 인스티튜트 오브 테크놀로지 | 헌팅톤병 및 레트 증후군에서의 장 미생물총의 조정 |
| US10596206B1 (en) | 2017-03-14 | 2020-03-24 | Cornell University | Probiotic compositions and methods of use |
| CA3211208A1 (en) | 2017-04-03 | 2018-10-11 | Gusto Global, Llc | Rational design of microbial-based biotherapeutics |
| EP3606541A1 (en) | 2017-04-05 | 2020-02-12 | Crestovo Holdings LLC | Compositions and methods for treating parkinson's disease (pd) and related disorders |
| WO2018187464A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| MX389322B (es) | 2017-04-28 | 2025-03-20 | Native Microbials Inc | Metodos para complementar dietas con alto consumo de granos y/o alto valor energetico en rumiantes, mediante la administracion de un bioensamble sintetico de microbios, o cepas purificadas de los mismos |
| EP3624818A4 (en) | 2017-05-19 | 2021-04-14 | Memorial Sloan-Kettering Cancer Center | METHODS AND COMPOSITIONS FOR REDUCING INFECTION OR COLONIZATION WITH LISTERIA MONOCYTOGENES |
| MA48940A (fr) | 2017-05-22 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41708A (fr) | 2017-05-24 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| CN110996917A (zh) | 2017-05-26 | 2020-04-10 | 克雷斯顿沃控股公司 | 包含基于粪便微生物的治疗剂的冻干组合物及其制造和使用方法 |
| TWI767013B (zh) | 2017-06-14 | 2022-06-11 | 英商4D製藥研究有限公司 | 包含細菌品系之組成物 |
| PL3638271T3 (pl) | 2017-06-14 | 2021-03-22 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
| JP2020523326A (ja) | 2017-06-14 | 2020-08-06 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| GB201709763D0 (en) * | 2017-06-19 | 2017-08-02 | Probi Ab | Biological materials and methods |
| AU2018309153A1 (en) * | 2017-08-04 | 2020-03-19 | Tarunmeet GUJRAL | Roseburia hominis, Eubacterium eligens, and combinations thereof as biotherapeutics |
| JP2020530493A (ja) * | 2017-08-07 | 2020-10-22 | フィンチ セラピューティクス、インコーポレイテッド． | 腸内の抗生物質耐性菌を除菌するための組成物及び方法 |
| KR20200038506A (ko) | 2017-08-07 | 2020-04-13 | 핀치 테라퓨틱스, 인코포레이티드 | 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법 |
| BR112020002992A2 (pt) | 2017-08-14 | 2020-08-18 | Seres Therapeutics, Inc. | composições e métodos para tratamento de doença colestática |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| WO2019046646A1 (en) | 2017-08-30 | 2019-03-07 | Whole Biome Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
| JP2021501185A (ja) | 2017-10-30 | 2021-01-14 | セレス セラピューティクス インコーポレイテッド | 抗生物質耐性を処置するための組成物及び方法 |
| EP3476396A1 (en) * | 2017-10-31 | 2019-05-01 | Institut Gustave Roussy | Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same |
| AU2018365071B2 (en) * | 2017-11-09 | 2025-09-11 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of allergy |
| EP4410954A3 (en) * | 2017-12-11 | 2025-01-15 | Vedanta Biosciences, Inc. | Compositions and methods for suppressing pathogenic organisms |
| US20200368293A1 (en) * | 2018-01-18 | 2020-11-26 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of cancer |
| JP2021512638A (ja) | 2018-02-09 | 2021-05-20 | 学校法人慶應義塾 | Ｃｄ８＋ｔ細胞の誘導のための組成物および方法 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| EP3594321A1 (en) | 2018-07-10 | 2020-01-15 | Université catholique de Louvain | Dusodibacter, a novel bacterial genus of the gastroinstestinal microbiota and uses thereof |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| CN113164526A (zh) | 2018-07-19 | 2021-07-23 | 潘德勒姆治疗公司 | 用于微生物植入的方法和组合物 |
| DE102018213030A1 (de) * | 2018-08-03 | 2020-02-06 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Behandlung von Immunerkrankungen durch die antikörpervermittelte Neutralisierung spezifischer Darmbakterien |
| JP7558170B2 (ja) * | 2018-08-17 | 2024-09-30 | ヴェダンタ バイオサイエンシーズ インコーポレーテッド | 腸内毒素症を減少させ、微生物叢を復元する方法 |
| CN113164527A (zh) | 2018-09-27 | 2021-07-23 | 芬奇治疗控股有限责任公司 | 用于治疗癫痫和相关障碍的组合物和方法 |
| WO2020071463A1 (ja) * | 2018-10-04 | 2020-04-09 | 国立研究開発法人理化学研究所 | ＩＬＣ２を標的としたＩｇＡ産生誘導方法 |
| CA3118679A1 (en) * | 2018-11-05 | 2020-05-14 | The University Of Chicago | Methods and compositions for treating infectious, autoimmune, and allergic disease |
| AU2019384816A1 (en) | 2018-11-21 | 2021-06-24 | Board Of Regents, The University Of Texas System | Methods and compositions for treating cancer |
| WO2020234746A1 (en) | 2019-05-18 | 2020-11-26 | Janssen Biotech, Inc. | Materials and methods for microbiome modulation |
| WO2021011887A1 (en) * | 2019-07-17 | 2021-01-21 | University Of Utah Research Foundation | Clostridia consortia compositions and methods of treating obesity, metabolic syndrome and irritable bowel disease |
| WO2021016081A1 (en) | 2019-07-19 | 2021-01-28 | Finch Therapeutics Holdings Llc. | Methods and products for treatment of gastrointestinal disorders |
| CN114502720A (zh) * | 2019-08-14 | 2022-05-13 | 瓦格宁根大学 | 包含myo-肌醇至丙酸途径的细菌 |
| JP2022544615A (ja) | 2019-08-16 | 2022-10-19 | ヤンセン バイオテツク，インコーポレーテツド | クロストリジウム属細菌の最適化された培養培地 |
| WO2021033043A1 (en) | 2019-08-16 | 2021-02-25 | Janssen Biotech, Inc. | Optimized culture media for clostridia bacteria |
| WO2021033042A1 (en) | 2019-08-16 | 2021-02-25 | Janssen Biotech, Inc. | Optimized culture media for clostridia bacteria |
| JP2021045097A (ja) * | 2019-09-20 | 2021-03-25 | 腸内フローラ移植臨床研究株式会社 | 腸内フローラの健康状態の診断方法及びその利用 |
| CN115243697A (zh) * | 2019-11-22 | 2022-10-25 | 未知君有限责任公司 | 包含细菌物种的组合物及其相关方法 |
| EP4125969A1 (en) * | 2020-03-25 | 2023-02-08 | Institut National de la Santé et de la Recherche Médicale (INSERM) | New strategy to treat and prevent diseases caused by enterobacteriae |
| EP3895710A1 (en) | 2020-04-15 | 2021-10-20 | DSM IP Assets B.V. | Food and/or feed compositions to manage immune homeostasis |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US20230201276A1 (en) * | 2020-05-21 | 2023-06-29 | Superbrewed Food, Inc. | Method of treating or preventing an infection |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| US12011467B2 (en) | 2021-05-18 | 2024-06-18 | J. Craig Venter Institute, Inc. | Bacterial formulation |
| CN116195742B (zh) * | 2021-11-30 | 2024-07-09 | 内蒙古伊利实业集团股份有限公司 | 乳双歧杆菌bl-99在保护软骨中的应用 |
| JPWO2023100977A1 (enExample) * | 2021-12-02 | 2023-06-08 | ||
| CN114917252A (zh) * | 2021-12-29 | 2022-08-19 | 慕恩（广州）生物科技有限公司 | 毛螺菌科微生物菌株、预防和/或治疗肿瘤的药物及应用 |
| CN119970806B (zh) * | 2025-02-25 | 2026-03-03 | 浙江大学 | 多毛假解黄酮菌在制备预防、治疗和/或改善溃疡性结肠炎的药物中的应用 |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3071122D1 (en) | 1979-11-16 | 1985-10-31 | Sterosynt Ltd | 6-alpha-fluoro-9-alpha-chloro-prednisolone-17,21 diesters, pharmaceutical compositions containing them and intermediates |
| US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| US5599795A (en) | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
| US5700787A (en) | 1994-09-02 | 1997-12-23 | Brigham & Women's Hospital, Inc. | Capsular polysaccharide immunomodulator |
| EP0952773B1 (en) | 1995-09-15 | 2005-11-23 | Dale N. Gerding | Methods and compositions for prevention and treatment of clostridium difficile-associated diseases |
| US6368586B1 (en) | 1996-01-26 | 2002-04-09 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
| CA2249189A1 (en) | 1996-03-20 | 1997-09-25 | The University Of New South Wales | Alteration of microbial populations in the gastrointestinal tract |
| US5922352A (en) | 1997-01-31 | 1999-07-13 | Andrx Pharmaceuticals, Inc. | Once daily calcium channel blocker tablet having a delayed release core |
| US6551632B2 (en) | 1997-04-01 | 2003-04-22 | Thomas Julius Borody | Methods and compositions for treating inflammatory bowel disease |
| ID29150A (id) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
| JP2001112485A (ja) | 1999-10-19 | 2001-04-24 | Yakult Honsha Co Ltd | 腸内細菌用プライマー及び該プライマーを用いた検出方法 |
| FR2808689B1 (fr) | 2000-05-11 | 2004-09-03 | Agronomique Inst Nat Rech | Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs |
| US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| SV2003000753A (es) | 2000-12-05 | 2003-06-16 | Brigham & Womens Hospital | Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico |
| WO2002080963A1 (en) | 2001-04-05 | 2002-10-17 | Virginia Mason Research Center | Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment |
| PE20030283A1 (es) | 2001-07-26 | 2003-05-01 | Alimentary Health Ltd | Cepas de lactobacillus casei |
| GB0220809D0 (en) * | 2002-09-06 | 2002-10-16 | Univ College Of London | Immune modulator |
| GB0307026D0 (en) | 2003-03-27 | 2003-04-30 | Rowett Res Inst | Bacterial supplement |
| AU2004227852B2 (en) | 2003-03-31 | 2010-01-14 | The Brigham And Women's Hospital, Inc. | Zwitterionic immunomodulators for the treatment of asthma and allergy |
| WO2004104175A2 (en) | 2003-05-14 | 2004-12-02 | University Of Georgia Research Foundation, Inc. | Probiotic bacteria and methods |
| JP2005124495A (ja) | 2003-10-24 | 2005-05-19 | Yakult Honsha Co Ltd | ヒト腸内細菌検出用プライマー |
| JPWO2005094886A1 (ja) | 2004-03-31 | 2008-02-14 | キリンファーマ株式会社 | Ｇｐｉアンカー蛋白質アゴニストによる調節性ｔ細胞分化誘導・増殖方法およびそのための医薬組成物 |
| US8092793B2 (en) | 2004-12-15 | 2012-01-10 | Qingdao East Sea Pharmaceuticals, Ltd. | Treating inflammatory bowel disease with live bacteria |
| CN101171019B (zh) | 2005-03-03 | 2012-05-23 | 株式会社明治 | 免疫功能调节剂 |
| CU23581A1 (es) * | 2005-10-28 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer |
| WO2007092451A2 (en) | 2006-02-06 | 2007-08-16 | The Brigham And Women's Hospital, Inc. | Zwitterionic polysaccharides for promotion of immune system maturation and health |
| DE102006062250A1 (de) | 2006-12-22 | 2008-06-26 | Roland Saur-Brosch | Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden |
| ES2399993T3 (es) | 2007-03-02 | 2013-04-04 | Protectimmun Gmbh | Composición farmacéutica para la protección frente a alergias y enfermedades inflamatorias |
| EP1974743A1 (en) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics to Improve Gut Microbiota |
| CN101310730A (zh) | 2007-05-27 | 2008-11-26 | 青岛东海药业有限公司 | 酪酸梭菌在制备防治类风湿性关节炎、强直性脊柱炎微生物制剂中的应用 |
| JP2009084215A (ja) | 2007-09-28 | 2009-04-23 | Nippon Paper Chemicals Co Ltd | 炎症性腸疾患予防・治療剤 |
| WO2009050486A2 (en) | 2007-10-19 | 2009-04-23 | The University Of Surrey | Peptide manipulators of regulatory t cell activity |
| US20090124573A1 (en) | 2007-11-09 | 2009-05-14 | Sarkis Mazmanian | Immunomodulating compounds and related compositions and methods |
| CN101496819A (zh) | 2008-01-31 | 2009-08-05 | 青岛东海药业有限公司 | 真杆菌、梭菌制剂及其应用 |
| KR100913405B1 (ko) | 2008-03-25 | 2009-08-21 | 광주과학기술원 | Ｔｈ２－매개 면역 질환의 예방 또는 치료용 조성물 |
| US8586029B2 (en) | 2008-06-04 | 2013-11-19 | Trustees Of Dartmouth College | Prevention or treatment of immune-relevant disease by modification of microfloral populations |
| JP2010129134A (ja) | 2008-11-28 | 2010-06-10 | Pulstec Industrial Co Ltd | ホログラム記録装置及びホログラム再生装置 |
| ES2799891T3 (es) | 2009-02-13 | 2020-12-22 | Univ California | Dispositivo, composición y método para el diagnóstico basado en tejidos |
| GB0903016D0 (en) | 2009-02-23 | 2009-04-08 | Univ Gent | Method for alleviating intestinal problems and novel bacterial strains therefor |
| CN102413826A (zh) | 2009-03-13 | 2012-04-11 | 达·沃尔泰拉公司 | 用于消除革兰氏阴性菌的组合物和方法 |
| EP2422200A4 (en) | 2009-04-23 | 2013-02-27 | California Inst Of Techn | METHOD AND SYSTEMS FOR IDENTIFYING IMMUNOMODULATIVE SUBSTANCES |
| US20100311686A1 (en) | 2009-06-03 | 2010-12-09 | Kasper Lloyd H | Nutraceutical composition and methods for preventing or treating multiple sclerosis |
| WO2011005756A1 (en) | 2009-07-06 | 2011-01-13 | Puretech Ventures, Llc | Delivery of agents targeted to microbiota niches |
| WO2011022542A2 (en) | 2009-08-19 | 2011-02-24 | Puretech Ventures, Llc | Administration of factors normally present in a microbial niche to improve health |
| US20120149584A1 (en) | 2009-08-21 | 2012-06-14 | Bernat Olle | Methods of diagnosing and treating microbiome-associated disease using interaction network parameters |
| WO2011027956A2 (ko) | 2009-09-04 | 2011-03-10 | 주식회사이언메딕스 | 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델 |
| US20120276149A1 (en) * | 2009-10-15 | 2012-11-01 | Dan Littman | Methods for modulating bacterial infection |
| RU2557310C2 (ru) | 2009-11-11 | 2015-07-20 | Алиментари Хелс Лимитед | ШТАММ Bifidobacterium longum, ПРИГОДНЫЙ ДЛЯ ПРИМЕНЕНИЯ В ИММУНОМОДУЛЯЦИИ, ИНДУКЦИИ ПРОДУКЦИИ ЦИТОКИНОВ, ЛЕЧЕНИИ АУТОИММУННОГО ЗАБОЛЕВАНИЯ, КОНТРОЛЕ ОТНОШЕНИЯ IL - 10:IL - 12, И ЕГО ИСПОЛЬЗОВАНИЕ |
| EP2556835B1 (en) * | 2010-02-10 | 2015-08-05 | Japan Eco-Science Co. Ltd. | Mixture, dissolving solution and pharmaceutical agent each comprising thermophilic microorganism |
| WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| WO2012013861A2 (en) | 2010-07-26 | 2012-02-02 | Suomen Punainen Risti Veripalvelu | Use of blood group status iii |
| US20120020941A1 (en) | 2010-07-26 | 2012-01-26 | Suomen Punainen Risti Veripalvelu | Use of blood group status iii |
| ES2388662B1 (es) | 2010-11-10 | 2014-04-11 | Consejo Superior De Investigaciones Científicas (Csic) | Nuevas cepas de duganella aisladas de la rizosfera de olivo silvestre y cultivado y su uso en la producción de violaceína. |
| US20120279149A1 (en) * | 2011-05-04 | 2012-11-08 | Sebastian George Quinn | System and device for utilization of energy in buildings |
| WO2012170478A2 (en) * | 2011-06-06 | 2012-12-13 | The University Of North Carolina At Chapel Hill | Methods and kits for detecting adenomas, colorectal cancer, and uses thereof |
| EP2756071B1 (en) | 2011-09-14 | 2017-12-20 | University Of Guelph | Media supplements and methods to culture human gastrointestinal anaerobic microorganisms |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| CA2892588A1 (en) * | 2011-12-01 | 2013-06-06 | School Corporation, Azabu Veterinary Medicine Educational Institution | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
| MX2015006491A (es) | 2012-11-23 | 2015-12-03 | Seres Health Inc | Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas. |
| CN104918624A (zh) | 2012-11-26 | 2015-09-16 | 托马斯·朱利叶斯·波洛迪 | 恢复排泄物微生物群的组合物及其制造和使用方法 |
| MX369877B (es) | 2013-02-04 | 2019-11-25 | Seres Therapeutics Inc | Composiciones y metodos. |
| US20160040215A1 (en) | 2013-03-14 | 2016-02-11 | Seres Therapeutics, Inc. | Methods for Pathogen Detection and Enrichment from Materials and Compositions |
| US9907755B2 (en) | 2013-03-14 | 2018-03-06 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| JP2016519664A (ja) | 2013-03-15 | 2016-07-07 | セレス セラピューティクス インコーポレイテッド | ネットワークを基にした微生物組成物及び方法 |
| US9764019B2 (en) * | 2013-07-09 | 2017-09-19 | Vedanta Biosciences, Inc. | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease |
| WO2015156419A1 (en) | 2014-04-10 | 2015-10-15 | Riken | Compositions and methods for induction of th17 cells |
| WO2015198105A1 (en) | 2014-06-27 | 2015-12-30 | Telefonaktiebolaget L M Ericsson (Publ) | System and method for supporting time-sensitive services in a communication network |
| MX381919B (es) | 2014-06-30 | 2025-03-13 | Salix Pharmaceuticals Inc | Métodos para repetir tratamiento de síndrome del intestino irritable (ibs). |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| CA2987013C (en) | 2015-05-30 | 2022-05-31 | Japan Eco-Science Co., Ltd. | Probiotic or prebiotic, method for producing same, microbial preparation, health food, and medicine |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| US9642281B1 (en) * | 2015-12-28 | 2017-05-02 | Martas Precision Slide Co., Ltd. | Buckle set for sliding rail of industrial rackmount chassis |
| AU2017234120B2 (en) * | 2016-03-14 | 2024-06-20 | Holobiome, Inc. | Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system |
| US11260083B2 (en) | 2016-03-15 | 2022-03-01 | The Regents Of The University Of Michigan | Compositions and methods for treating and preventing graft versus host disease |
| US20170290889A1 (en) | 2016-04-11 | 2017-10-12 | New York University | Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders |
| JP6792103B2 (ja) | 2016-06-01 | 2020-11-25 | 株式会社テックコーポレーション | 微細気泡水供給システム |
| KR102658297B1 (ko) | 2016-06-14 | 2024-04-18 | 베단타 바이오사이언시즈, 인크. | 클로스트리디움 디피실레 감염의 치료 |
| CA3041277A1 (en) | 2016-11-01 | 2018-05-11 | Keio University | Bacterium capable of inducing th1 cells |
| BR112019013125B1 (pt) * | 2016-12-23 | 2022-02-08 | Keio University | Composições farmacêuticas compreendendo uma mistura bacteriana purificada |
| JP2020530493A (ja) | 2017-08-07 | 2020-10-22 | フィンチ セラピューティクス、インコーポレイテッド． | 腸内の抗生物質耐性菌を除菌するための組成物及び方法 |
| JP2019046634A (ja) * | 2017-08-31 | 2019-03-22 | パナソニックＩｐマネジメント株式会社 | 照明システム及びコントローラ |
| AU2018365071B2 (en) * | 2017-11-09 | 2025-09-11 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of allergy |
| EP4410954A3 (en) | 2017-12-11 | 2025-01-15 | Vedanta Biosciences, Inc. | Compositions and methods for suppressing pathogenic organisms |
| JP2021512638A (ja) | 2018-02-09 | 2021-05-20 | 学校法人慶應義塾 | Ｃｄ８＋ｔ細胞の誘導のための組成物および方法 |
| JP7558170B2 (ja) | 2018-08-17 | 2024-09-30 | ヴェダンタ バイオサイエンシーズ インコーポレーテッド | 腸内毒素症を減少させ、微生物叢を復元する方法 |
| WO2020234746A1 (en) | 2019-05-18 | 2020-11-26 | Janssen Biotech, Inc. | Materials and methods for microbiome modulation |
| EP4362961A1 (en) | 2021-06-28 | 2024-05-08 | Vedanta Biosciences, Inc. | Methods of colonizing a microbiome, treating and/or preventing inflammatory bowel disease and graft versus host disease |
-
2012
- 2012-11-29 CA CA2892588A patent/CA2892588A1/en active Pending
- 2012-11-29 DK DK19178787.8T patent/DK3569690T3/da active
- 2012-11-29 ES ES19178787T patent/ES2994320T3/es active Active
- 2012-11-29 EP EP24196410.5A patent/EP4477750A3/en active Pending
- 2012-11-29 CN CN201280068081.8A patent/CN104160014A/zh active Pending
- 2012-11-29 JP JP2014526308A patent/JP6306507B2/ja active Active
- 2012-11-29 CN CN202310526067.8A patent/CN116942833A/zh active Pending
- 2012-11-29 FI FIEP19178787.8T patent/FI3569690T3/fi active
- 2012-11-29 HK HK15104633.8A patent/HK1204008A1/xx unknown
- 2012-11-29 EP EP21198256.6A patent/EP3978598B1/en active Active
- 2012-11-29 CN CN201810228890.XA patent/CN108676774B/zh active Active
- 2012-11-29 WO PCT/JP2012/007687 patent/WO2013080561A1/en not_active Ceased
- 2012-11-29 EP EP12854485.5A patent/EP2785828B1/en active Active
- 2012-11-29 ES ES21198256T patent/ES2993669T3/es active Active
- 2012-11-29 DK DK21198256.6T patent/DK3978598T3/da active
- 2012-11-29 US US14/362,097 patent/US10238694B2/en active Active
- 2012-11-29 EP EP19178787.8A patent/EP3569690B1/en active Active
- 2012-11-29 FI FIEP21198256.6T patent/FI3978598T3/fi active
-
2016
- 2016-02-09 US US15/019,101 patent/US9649345B2/en active Active
- 2016-02-09 US US15/019,068 patent/US9642881B2/en active Active
-
2017
- 2017-03-28 US US15/471,493 patent/US10052353B2/en active Active
- 2017-04-14 US US15/487,553 patent/US10058578B2/en active Active
- 2017-11-06 JP JP2017213526A patent/JP6492151B2/ja active Active
-
2018
- 2018-04-27 US US15/964,285 patent/US10183045B2/en active Active
- 2018-10-15 US US16/160,004 patent/US10342832B2/en active Active
- 2018-10-25 US US16/170,344 patent/US10835559B2/en active Active
-
2019
- 2019-03-04 JP JP2019038453A patent/JP7097838B2/ja active Active
- 2019-05-31 US US16/427,899 patent/US10624933B2/en active Active
-
2020
- 2020-10-15 US US17/071,425 patent/US11547732B2/en active Active
-
2021
- 2021-01-18 JP JP2021005834A patent/JP7165218B2/ja active Active
-
2022
- 2022-10-21 JP JP2022168855A patent/JP7503273B2/ja active Active
- 2022-12-20 US US18/068,725 patent/US12502411B2/en active Active
-
2024
- 2024-05-30 JP JP2024087782A patent/JP2024129016A/ja active Pending
-
2025
- 2025-10-20 US US19/363,084 patent/US20260158080A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018039833A5 (enExample) | ||
| US11825848B2 (en) | Method of identifying a biologically-active composition from a biofilm | |
| Wang et al. | Probiotics to prevent respiratory infections in nursing homes: a pilot randomized controlled trial | |
| Meini et al. | Breakthrough Lactobacillus rhamnosus GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis: case report and review of the literature | |
| Waki et al. | Oral administration of Lactobacillus brevis KB290 to mice alleviates clinical symptoms following influenza virus infection | |
| JP2024129016A5 (enExample) | ||
| EP3209381B1 (en) | Compositions comprising bacterial strains | |
| BR112013016690A2 (pt) | agente para induzir a produção de ifn, agente imunopotencializador, agente para prevenção ou tratamento de infecção viral, produto comestível ou bebível, método de triagem de bactérias do ácido lático, microrganismo hospedeiro para uma vacina recombinante | |
| Coleman et al. | Probiotics in the treatment of otitis media. The past, the present and the future | |
| JP2021527104A5 (enExample) | ||
| JP2021501185A5 (enExample) | ||
| Neau et al. | Three novel candidate probiotic strains with prophylactic properties in a murine model of cow's milk allergy | |
| Chi et al. | Real-time induction of macrophage apoptosis, pyroptosis, and necroptosis by Enterococcus faecalis OG1RF and two root canal isolated strains | |
| JP2016509003A5 (enExample) | ||
| CN109715179A (zh) | 用于治疗皮肤病症的组合物和方法 | |
| RU2011139211A (ru) | Бактериальные штаммы, обладающие высокой противовоспалительной активностью | |
| JP2019500056A5 (enExample) | ||
| JP2019522649A (ja) | 健康な皮膚微生物叢の維持及び／又は回復に対する皮膚科調合剤 | |
| JP2020520916A5 (enExample) | ||
| JP2022501330A5 (enExample) | ||
| Kang et al. | A recombinant Bifidobacterium bifidum BGN4 strain expressing the streptococcal superoxide dismutase gene ameliorates inflammatory bowel disease | |
| CN119948147A (zh) | 巨大芽孢杆菌菌株、其组合物及使用方法 | |
| Tamura et al. | Peptides from rice endosperm protein restrain periodontal bone loss in mouse model of periodontitis | |
| Lee et al. | Immunomodulatory Properties and Ameliorative Effects of Pediococcus inopinatus in an Animal Model of Inflammatory Bowel Disease | |
| Gardiner et al. | Evaluation of colostrum-derived human mammary-associated serum amyloid A3 (M-SAA3) protein and peptide derivatives for the prevention of enteric infection: in vitro and in murine models of intestinal disease |